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A Fifty- Two–Week, Randomized, Placebo- Controlled 
Trial of Certolizumab Pegol in Nonradiographic Axial 
Spondyloarthritis
Atul Deodhar,1 Lianne S. Gensler,2 Jonathan Kay,3  Walter P. Maksymowych,4 Nigil Haroon,5  
Robert Landewé,6 Martin Rudwaleit,7 Stephen Hall,8 Lars Bauer,9 Bengt Hoepken,9 Natasha de Peyrecave,10 
Brian Kilgallen,11 and Désirée van der Heijde12
Objective. The natural history of nonradiographic axial spondyloarthritis (SpA) is incompletely characterized, and 
there are concerns that nonsteroidal antiinflammatory drugs provide inadequate disease control in patients with ac-
tive disease. This study was undertaken to investigate the effects of certolizumab pegol (CZP), an anti–tumor necrosis 
factor treatment, in patients with nonradiographic axial SpA with objective signs of inflammation.
Methods. In this ongoing parallel- group double- blind study, adults with active disease were recruited from 80 
centers in Australia, Europe, North America, and Taiwan, and were randomized 1:1 to receive placebo or CZP (400 mg 
at weeks 0, 2, and 4, followed by 200 mg every 2 weeks) in addition to nonbiologic background medication (NBBM). 
Switching to open- label CZP (or other biologic) or making background medication changes was permitted at any 
point during the trial, although changes before week 12 were discouraged. The primary end point was the proportion 
of patients achieving major improvement (MI) (i.e., a ≥2.0- point decrease in the score from baseline or achievement 
of the lowest possible score [0.6]) in the Ankylosing Spondylitis Disease Activity Score (ASDAS) at week 52.
Results. A total of 317 patients were randomized to receive placebo plus NBBM (n = 158) or CZP plus NBBM  
(n = 159). ASDAS- MI at week 52 was achieved in 47.2% (75 of 159) of CZP plus NBBM patients, which was sig-
nificantly greater (P < 0.0001) than the 7.0% (11 of 158) of placebo plus NBBM patients in whom ASDAS-MI was 
achieved. Of the placebo plus NBBM patients, 60.8% (96 of 158) switched to open- label treatment before week 52 
compared to 12.6% (20 of 159) of the CZP plus NBBM patients.
Conclusion. Adding CZP to background medication is superior to adding placebo in patients with active non-
radiographic axial SpA. These results indicate that remission in nonradiographic axial SpA treated without biologics 
occurs infrequently, demonstrating the need for treatment beyond nonbiologic therapy.
ClinicalTrials.gov identifier: NCT02552212.
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INTRODUCTION
Axial spondyloarthritis (SpA) is a chronic inflammatory dis-
ease predominantly affecting the sacroiliac joints and spine. The 
disease comprises 2 subpopulations: those with radiographic 
axial SpA (also known as ankylosing spondylitis) and those with 
nonradiographic axial SpA, who have been reported to have a 
similar disease burden (1–6). Conventional therapy for axial SpA 
comprises nonpharmacologic management, such as physical 
therapy, and nonsteroidal antiinflammatory drugs (NSAIDs) as 
first- line treatment. In routine clinical practice, patients are also 
treated with conventional disease- modifying antirheumatic 
drugs (DMARDs), corticosteroids, and analgesics. However, for 
patients with active disease and objective signs of inflammation 
 (sacr oiliac joint inflammation on magnetic resonance imaging 
[MRI] or elevated C- reactive protein [CRP] level) despite treat-
ment with NSAIDs, treatment with anti–tumor necrosis factor 
(anti- TNF) agents has been recommended (7–10).
There is a lack of understanding of disease presentation, pro-
gression, and prognosis of nonradiographic axial SpA (11–14). It 
has been suggested that nonradiographic axial SpA could be a 
self- limiting disease, with the potential for spontaneous remission 
(15–18). This, in part, has resulted in the lack of access to anti- TNF 
agents for many patients with nonradiographic axial SpA in several 
countries.
The C- axSpAnd Study is the first to incorporate a 52- week 
placebo- controlled time period to investigate the efficacy of an 
anti- TNF agent, certolizumab pegol (CZP), in a population of non-
radiographic axial SpA patients. This study employed a unique 
design that incorporated a long placebo- controlled phase, which 
permitted optimization of nonbiologic treatment over a sufficiently 
long time frame to assess disease remission.
PATIENTS AND METHODS
Study design. The C- axSpAnd Study (ClinicalTrials.gov 
identifier: NCT02552212) is a 3- year, phase III multicenter study 
investigating the efficacy and safety of CZP in patients with non-
radiographic axial SpA. Patients were randomized to receive 
either CZP or placebo in addition to their current nonbiologic 
background medication (NBBM) at 80 sites located in Australia, 
Europe, North America, and Taiwan, in a 52- week, parallel- 
group, double- blind, placebo- controlled study. The primary 
objective of the study was to assess the efficacy of CZP 200 mg 
every 2 weeks on signs and symptoms in patients with active 
nonradiographic axial SpA who had previously been treated 
unsuccessfully with ≥2 NSAIDs.
This study was approved by the national, regional, or inde-
pendent ethics committees or institutional review boards at par-
ticipating sites and was conducted in accordance with applicable 
regulatory and International Conference on Harmonization Good 
Clinical Practice requirements, based on the Declaration of Helsinki 
and local laws. Protocol amendments after the commencement of 
the trial are provided in Supplementary Appendix A, available on 
the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.40866/abstract.
Patients. Eligible patients were required to 1) be age ≥18 
years, 2) have a documented diagnosis of adult- onset axial 
SpA, meeting the Assessment of SpondyloArthritis international 
Society (ASAS) classification criteria (19), 3) have ≥12 months 
of symptom duration, and 4) have active disease at screening 
and baseline (defined as a Bath Ankylosing Spondylitis Disease 
Activity Index [BASDAI] [20] score of ≥4 and spinal pain score 
of ≥4 on a 0–10 scale) despite treatment with NBBMs, includ-
ing ≥2 NSAIDs. Patients with radiographic sacroiliitis meeting 
the modified New York classification criteria (21)  were excluded 
from the trial. Patients were also required to have objective 
signs of inflammation, i.e., either active sacroiliitis as evidenced 
by MRI (based on the ASAS definition of a positive MRI [22]) 
at screening or a baseline CRP level above the upper limit of 
normal (defined as 10.0 mg/liter). Pelvic radiographs and MRI 
scans were read centrally by 2 readers (and by an adjudicator, 
if necessary). For full patient selection criteria, see Supplemen-
tary Appendix B, available on the Arthritis & Rheumatology web 
site at http://onlinelibrary.wiley.com/doi/10.1002/art.40866/
abstract. All patients provided written informed consent to 
participate in the study.
Randomization and masking. Patients were randomized 
1:1 using an interactive response system that allocated and main-
tained all treatment details. Due to the differences in presentation 
and viscosity between CZP and placebo, special precautions were 
taken to maintain the blinding, including provision of the study treat-
ment in a sealed box with a prefilled syringe containing either CZP 
200 mg or placebo, and there was no information about the study 
treatment on packaging or labeling. Members of the study team 
were blinded with regard to the randomization schedule until after 
database lock and unblinding. For patients who switched to open- 
label treatment with CZP or any other treatment, efforts were made 
to maintain blinding with regard to their prior double- blind study 
treatment. Randomization was stratified based on MRI and CRP 
status (MRI+/CRP+, MRI+/CRP−, and MRI−/CRP+), as well as by 
geographic region (Asia/Australia, Europe, and North America).
UCB Pharma will share anonymized patient-level data and additional inform-
ation including clinical study report, study protocols, and statistical analysis plan.
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Procedures. Study treatment (CZP or placebo) was 
administered via a prefilled syringe. CZP was given at a dose of 
400 mg at weeks 0, 2, and 4 (loading dose) followed by 200 mg 
every 2 weeks (Supplementary Figure 1, available on the Arthri-
tis & Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.40866/abstract). At the discretion of the treat-
ing rheumatologist, NBBM for this disease could be adjusted 
at any time during the trial; however, changes before week 12, 
or within 4 weeks prior to weeks 24 and 52, were discouraged. 
NBBMs allowed in this study included NSAIDs, conventional 
DMARDs such as sulfasalazine, methotrexate, hydrochloro-
quine, oral and intravenous corticosteroids, and opioid and non-
opioid analgesics (Table 1 and Supplementary Table 1, available 
on the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40866/abstract). To reflect the provi-
sion of NBBM, the treatment groups are hereafter referred to as 
Table 1. Patient demographic and clinical characteristics at baseline (n = 317)*
Placebo plus 
NBBM group 
(n = 158)
CZP plus 
NBBM, 
200 mg every 
2 weeks 
(n = 159)
ASQoL score, mean  
± SD 
12.1 ± 4.3 11.7 ± 4.3
Uveitis 
History 25 (15.8) 22 (13.8)
Current 11 (7.0) 6 (3.8)
Enthesitis 122 (77.2) 125 (78.6)
MASES, mean ± SD 4.8 ± 3.5 4.8 ± 3.2
ASAS- NSAID score, mean 
± SD
66.3 ± 48.7 69.6 ± 48.0
MRI/CRP stratification†
MRI+/CRP+ 42 (26.6) 45 (28.3)
MRI+/CRP− 76 (48.1) 74 (46.5)
MRI−/CRP+ 39 (24.7) 38 (23.9)
Prior and concomitant 
medications
NSAIDs
Prior 154 (97.5) 157 (98.7)
Concomitant 138 (87.3) 138 (86.8)
DMARDs
Prior 73 (46.2) 77 (48.4)
Concomitant 48 (30.4) 55 (34.6)
Corticosteroids
Prior 36 (22.8) 31 (19.5)
Concomitant 16 (10.1) 16 (10.1)
Anti- TNF medication, any 
prior usage 
11 (7.0) 7 (4.4)
Placebo plus 
NBBM group 
(n = 158)
CZP plus 
NBBM, 
200 mg every 
2 weeks 
(n = 159)
Demographic characteristic
Age, mean ± SD years 37.4 ± 10.8 37.3 ± 10.5
Female 82 (51.9) 81 (50.9)
HLA–B27 positive 132 (83.5) 128 (80.5)
White race 148 (93.7) 152 (95.6)
Geographic region
North America 13 (8.2) 15 (9.4)
Europe 130 (82.3) 130 (81.8)
Asia/Australia 15 (9.5) 14 (8.8)
Disease characteristic
Symptom duration, mean ± 
SD years
8.0 ± 7.5 7.8 ± 7.7
Time since first diagnosis, 
years
Mean ± SD 4.0 ± 5.4 3.6 ± 4.8
Median (range) 2.1 (0.0–38.2) 1.7 (0.1–29.2)
CRP, mean ± SD mg/liter 15.8 ± 17.7 15.8 ± 17.8
Elevated CRP at baseline 
(CRP > ULN) 
83 (52.5) 89 (56.0)
ASDAS, mean ± SD 3.8 ± 0.9 3.8 ± 0.8
BASDAI score, mean ± SD 6.8 ± 1.3 6.9 ± 1.4
BASFI score, mean ± SD 5.4 ± 2.2 5.4 ± 2.1
BASMI score, mean ± SD 2.8 ± 1.4 3.0 ± 1.3
Sacroiliac joint SPARCC 
score, mean ± SD
8.5 ± 12.3 7.8 ± 10.8
Nocturnal spinal pain score, 
mean ± SD (scale 0–10)
6.6 ± 2.1 6.6 ± 2.3
* Except where indicated otherwise, values are the number (%) of patients in the analysis population. NBBM = nonbiologic background 
medication; CZP = certolizumab pegol; ULN = upper limit of normal; ASDAS = Ankylosing Spondylitis Disease Activity Score; BASDAI = Bath 
Ankylosing Spondylitis Disease Activity Index (0–10 scale; higher scores indicate higher disease activity); BASFI = Bath Ankylosing Spondylitis 
Functional Index (0–10 scale; higher scores indicate worse function); BASMI = Bath Ankylosing Spondylitis Metrology Index (0–10 scale; higher 
scores indicate more severe spinal mobility impairment); SPARCC = Spondyloarthritis Research Consortium of Canada; ASQoL = ankylosing 
spondylitis quality of life (0–18 scale; higher scores indicate worse quality of life); MASES = Maastricht Ankylosing Spondylitis Enthesitis Score 
(0–13 scale; higher scores indicate more severe enthesitis); ASAS- NSAID score = Assessment of SpondyloArthritis international Society–non-
steroidal antiinflammatory drug score (0–100 scale; higher scores indicate greater NSAID intake); DMARDs = disease- modifying antirheumatic 
drugs; anti- TNF = anti–tumor necrosis factor. 
† Three patients were classified as magnetic resonance imaging negative (MRI−)/C- reactive protein negative (CRP−) and were determined to 
be protocol deviations. 
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placebo plus NBBM and CZP 200 mg with NBBM (CZP plus 
NBBM).
In addition, patients were able to switch to open- label CZP 
treatment or any other biologic at any point during the trial if 
their disease activity required escalation of treatment. Patients 
who had transitioned to open- label treatment continued to be 
followed up during the study. At the completion of the week- 
52 visit, eligible patients could receive CZP treatment for an 
additional 2 years in an open- label follow- up extension period. 
At the time of publication, patients in this study are receiving 
treatment as part of the open- label follow- up period. This study 
describes the results of the 52- week placebo- controlled period.
Outcome measures. The primary efficacy end point was 
defined as a composite outcome measure that was achieved if 
all of the following 3 criteria were fulfilled: 1) the patient remained 
in the study until week 52, 2) the patient continued taking 
double- blind study treatment throughout, and 3) the patient 
achieved major improvement (MI) in the Ankylosing Spondylitis 
Disease Activity Score (ASDAS) (23) at week 52. ASDAS- MI is 
defined as a ≥2.0- point decrease from the baseline score in the 
ASDAS or achievement of the lowest possible ASDAS value 
(0.6) (24). The ASDAS comprises the following 5 elements, 
which are algorithmically combined into a continuous measure 
of disease activity: patient’s self- reported back pain, peripheral 
pain/swelling in joints and duration of morning stiffness (all from 
the BASDAI questionnaire), Patient’s Global Assessment of Dis-
ease Activity (PGADA), and CRP level (25). All patient- reported 
outcome assessments were graded on a numerical rating scale 
(0–10). The measured CRP level (mg/liter; measured at a central 
laboratory) was used for ASDAS calculations, with a minimum 
value of 2 mg/liter as validated previously (24). Details regarding 
scoring and time points for each efficacy end point are provided 
in Supplementary Table 2, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.40866/abstract).
Key secondary efficacy end points within the statistical testing 
hierarchy included the following: achievement of 40% improve-
Figure 1. Disposition of the patients. † = some patients met/did not meet multiple eligibility criteria; therefore, patient numbers in the disposition 
of patients do not add up to the total number of ineligible patients. MRI = magnetic resonance imaging; CRP = C- reactive protein; ASAS = 
Assessment of SpondyloArthritis international Society; axSpA = axial spondyloarthritis; BASDAI = Bath Ankylosing Spondylitis Disease Activity 
Index; PBO = placebo; NBBM = nonbiologic background medication; CZP = certolizumab pegol 200 mg.
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ment according to the ASAS (ASAS40) at weeks 12 and 52, 
change from the baseline BASDAI score at weeks 12 and 52, 
change from the baseline Bath Ankylosing Spondylitis Functional 
Index (BASFI) score (26) at weeks 12 and 52, the Spondyloarthri-
tis Research Consortium of Canada (SPARCC) score for sacroiliac 
joints (27) at week 12, the Ankylosing Spondylitis Quality of Life 
(ASQoL) score (28) at week 52, nocturnal back pain at week 52, 
and the number of patients who had new or recurrent anterior uve-
itis flares at week 52 (Supplementary Table 2, at http://onlinelibrary.
wiley.com/doi/10.1002/art.40866/abstract). Exposure- adjusted 
incidence rates for postbaseline uveitis flares at week 52 were 
 calculated post hoc.
Additional outcomes not included in the hierarchical testing 
procedure were also evaluated. These included the EuroQoL 
5- domain Health State Profile (29), physical and mental compo-
nent scores of the Short Form 36 health survey (SF- 36) (30), the 
ASAS- NSAID score (a quantification of cumulative NSAID intake 
on a scale of 0–100, with 0 representing no intake and 100 repre-
senting maximum intake), the Bath Ankylosing Spondylitis Metrol-
ogy Index (BASMI) linear score (31), the week-52 SPARCC score, 
and enthesitis as measured by the Maastricht Ankylosing Spon-
dylitis Enthesitis Score (MASES) (32).
In addition, post hoc analyses of patients who contin-
ued taking placebo up to week 52 were conducted, including 
assessment of ASDAS- MI, ASAS40, and BASDAI. Finally, post 
hoc analyses were conducted to investigate the disease activity 
of patients at the point of switching from placebo to open- label 
CZP treatment.
Statistical analysis. The sample size was calculated using 
a chi- square test of equal proportions with continuity correction. 
A total sample size of 300 subjects (150 subjects per treatment 
group) was planned to provide 95% power to detect a significant 
difference in the ASDAS- MI response rate at week 52 between 
CZP and placebo groups, based on a 2- sided significance level 
of 0.05. This was based on the assumption of expected response 
rates for ASDAS- MI at week 52 of 40% and 20% for CZP and 
placebo groups, respectively.
The population studied in all efficacy analyses included all 
patients who underwent randomization and received ≥1 dose of 
study medication (full analysis set), analyzed based on the intent- 
to- treat principle. Safety outcomes are reported for the safety set, 
which consisted of all patients treated with ≥1 dose of study med-
ication.
The primary efficacy end point and the 10 key secondary effi-
cacy end points were tested for statistical significance according 
to a hierarchical testing procedure to maintain a familywise error 
rate of 5% (the full hierarchy is included in Supplementary Figure 
2, available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40866/abstract). Testing 
was conducted at a significance level of 0.05 (2- sided), starting 
with the primary efficacy end point and, if the null hypothesis was 
rejected, proceeding with the secondary efficacy end points in 
their prespecified order.
The primary efficacy end point was analyzed using a 
logistic regression model with treatment group, region, and 
MRI/CRP stratification as fixed effects. The odds ratio (OR) of the 
ASDAS- MI at week 52 was estimated and tested between treat-
ment groups. Patients completing week 52 taking double- blind 
treatment but with no available ASDAS score at this time point 
were classified as nonresponders.
Sensitivity analyses of the primary efficacy end point used 
alternate approaches for handling of missing data with various 
assumptions for missingness mechanisms, including re- analysis 
after multiple imputation, re- analysis with all available data 
regardless of whether a subject continued to receive the rand-
omized treatment (i.e., including post- escape data), tipping point 
analysis (i.e., various delta adjustments for the missing data 
were conducted to identify assumptions about the missing data, 
under which there is no longer evidence of a treatment effect), 
and observed case analysis (in which only observed data from 
patients who continued the original double- blind study treatment 
were included).
Figure 2. Proportion of patients achieving A, major improvement 
in the Ankylosing Spondylitis Disease Activity Score (ASDAS- MI) and 
B, 40% improvement in disease activity according to the Assessment 
of SpondyloArthritis international Society criteria (ASAS40) by week 
52. P < 0.0001 for certolizumab pegol (CZP) versus placebo (PBO) 
at week 12 and week 52 for both ASDAS- MI and ASAS40. NBBM = 
nonbiologic background medication.
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Continuous efficacy end points were analyzed using an 
analysis of covariance model with treatment group, region, and 
MRI/CRP classification as fixed effects and the baseline score 
as a covariate. The primary analysis used a reference- based 
multiple imputation procedure (in which missing values for both 
treatment groups were imputed using an imputation model 
developed using data from the placebo group only). Sensitivity 
analyses were conducted using multiple imputation, last obser-
vation carried forward, and observed case analysis.
Dichotomous secondary end points were analyzed via 
logistic regression based on a model similar to that used for the 
primary efficacy end point analysis. Safety outcomes were sum-
marized using descriptive statistics. All statistical analyses were 
performed using SAS, version 9.4.
RESULTS
From September 2015, 941 patients with nonradiographic 
axial SpA were screened at 104 sites, and 624 of these patients 
were excluded (Figure 1). A total of 317 patients were randomized 
to receive treatment as follows: 158 patients to the placebo plus 
NBBM group and 159 to the CZP plus NBBM group. In total, 
260 patients from Europe, 29 patients from Taiwan/Australia, and 
28 patients from North America were included. Baseline charac-
teristics of the patients were well- balanced between treatment 
groups (Table 1). Full details of NBBM at baseline in the 2 treat-
ment groups are provided in Supplementary Table 3, available on 
the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.40866/abstract.
The primary end point, ASDAS- MI at week 52, was reached 
by 47.2% (75 of 159) of CZP plus NBBM patients and 7.0% (11 of 
158) of placebo plus NBBM patients (P < 0.0001) (OR for CZP plus 
NBBM versus placebo plus NBBM 15.2 [95% confidence interval 
7.3–31.6]) (Figure 2A). All sensitivity analyses of the primary end 
point, performed in order to assess the impact of various missing 
data assumptions, supported the results of the primary analysis, 
with ORs ranging from 2.2 to 16.1 (Figure 3).
By week 52, 60.8% (96 of 158) of placebo plus NBBM 
patients compared to 12.6% (20 of 159) of CZP plus NBBM 
patients had switched to open- label treatment. No switches 
occurred between baseline and week 12; the majority of switches 
occurred between weeks 12 and 24. Of the 116 patients who 
switched to open- label CZP treatment prior to week 52, 1 patient 
subsequently switched to an alternative open- label anti- TNF 
treatment and then later discontinued the study prior to week 
52. In total, 69.6% (110 of 158) of placebo plus NBBM patients 
had changes to their background medication during the study, 
compared to 27.7% (44 of 159) of CZP plus NBBM patients. 
During the 52- week placebo- controlled period, 6.9% (22 of 317) 
of patients withdrew from the study for reasons outlined in Fig-
ure 1: 5.1% (8 of 158) withdrew from the placebo plus NBBM 
treatment group and 8.8% (14 of 159) from the CZP plus NBBM 
group. At week 52, 78.6% (125 of 159) of CZP plus NBBM 
patients had completed the 52- week placebo- controlled period 
taking double- blind study medication, compared to 34.2% (54 
of 158) of placebo plus NBBM patients.
All secondary end points within the prespecified hierarchical 
testing procedure could be tested (Table 2 and Supplementary 
Table 4, available on the Arthritis & Rheumatology web site at 
http://onlinelibrary.wiley.com/doi/10.1002/art.40866/abstract). 
At week 12, 47.8% (76 of 159) of CZP plus NBBM patients had 
achieved an ASAS40 response, compared to 11.4% (18 of 158) 
Figure 3. Forest plot of major improvement in the Ankylosing Spondylitis Disease Activity Score (ASDAS- MI) sensitivity analyses at week 52. 
95% CI = 95% confidence interval; FAS = full analysis set; PBO = placebo; CZP = certolizumab pegol 200 mg; PPS = per protocol set; NBBM 
= nonbiologic background medication.
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of placebo plus NBBM patients (P < 0.0001) (Figure 2B). By week 
52, 56.6% (90 of 159) of CZP plus NBBM patients and 15.8% (25 
of 158) of placebo plus NBBM patients had achieved an ASAS40 
response (P < 0.0001).
Clinically meaningful and statistically significant responses 
for the BASDAI and the BASFI were achieved in CZP plus 
NBBM–treated patients and are shown in Table 2. MRI inflam-
mation in the sacroiliac joints significantly improved in CZP plus 
NBBM–treated patients, decreasing from a mean ± SD sacro-
iliac joint SPARCC score of 7.79 ± 10.82 at baseline to 1.92 
± 3.96 at week 52, compared to 8.46 ± 12.31 in the placebo- 
treated population at baseline to 5.84 ± 10.99 at week 52 
(P < 0.0001) (Table  2). There were corresponding improve-
ments in nocturnal spinal pain in CZP plus NBBM–treated 
patients that were maintained to week 52 (Table  2). Similar 
improvements and sustained responses were observed in 
health- related quality of life outcomes such as the ASQoL and 
SF- 36 (Table 2). Postbaseline uveitis was observed in 2.5% (4 
of 159) of CZP plus NBBM patients compared to 5.1% (8 of 
158) of placebo plus NBBM patients, but this difference did 
not achieve statistical significance. Improvements were also 
observed in CZP plus NBBM–treated patients for additional 
end points tested (Table 2).
Treatment- emergent adverse events during the placebo- 
controlled period of the study are shown in Table 3. One malig-
nancy was reported in the placebo plus NBBM group, and 2 
malignancies were reported in the CZP plus NBBM group. There 
were no deaths, serious cardiovascular events, or opportunistic 
infections (including tuberculosis) during the trial. The adverse 
events reported were consistent with those already identified for 
CZP and other anti- TNF agents (33,34).
Fifty- four patients continued taking placebo plus NBBM 
throughout the 52- week period. Of these patients, 51 had 
assessments at week 52 for ASDAS- MI and ASAS40. Post hoc 
analysis revealed that 21.6% (11 of 51) reached ASDAS- MI, 
while 49.0% (25 of 51) achieved an ASAS40 response. Demo-
graphic details and NBBM use in the 11 placebo plus NBBM 
patients who reached ASDAS- MI are provided in Supplemen-
tary Table 5, available on the Arthritis & Rheumatology web 
site at http://onlinelibrary.wiley.com/doi/10.1002/art.40866/
abstract. The mean change from baseline in the BASDAI score 
in the 54 patients who continued taking placebo throughout 
the 52- week period was −2.90 ± 2.19, compared to −4.28 ± 
2.13 in the CZP- treated patients.
In post hoc analyses investigating the disease activity of 
patients switching from placebo to open- label CZP treatment, 
96.9% (93 of 96) of patients did not demonstrate an ASDAS- MI 
response at the time of switching. Additionally, 93.8% (90 of 96) 
and 87.5% (84 of 96) of patients were classified as ASAS40 and 
ASAS20 nonresponders, respectively. At the time of switching, 
the mean ± SD ASDAS and BASDAI values for these patients 
were 3.60 ± 0.93 and 6.56 ± 1.69, respectively.
DISCUSSION
The results from this 52- week placebo- controlled trial, 
conducted in patients with active nonradiographic axial SpA 
with objective signs of inflammation, highlight the efficacy of 
CZP in the nonradiographic axial SpA population, with clini-
cally relevant and statistically significant differences observed 
in the primary end points and all but 1 of the secondary end 
points, which addressed different aspects of the disease (e.g., 
disease activity, physical function, and pain). All sensitivity 
analyses, which used alternate approaches to handling miss-
ing data, confirmed these results. The only exception was the 
number of patients with anterior uveitis flares, although this 
should be interpreted with caution due to the small number of 
affected patients in each treatment group. Relevant improve-
ments with CZP plus NBBM treatment were also observed for 
additional outcomes, including objective signs of inflammation 
(MRI and CRP level), SPARCC at week 52, BASMI, MASES, 
and patient- reported quality of life outcomes. The favorable 
outcomes observed in this study are in accordance with pre-
vious phase III placebo- controlled trials that have evaluated 
the use of anti- TNF agents in nonradiographic axial SpA over 
shorter time frames, ranging from 12 to 16 weeks (1,35–37). 
In addition, safety outcomes were in accordance with those 
published previously (34).
The unique study design of the trial, which comprised a 
1- year placebo- controlled period, the ability to change back-
ground medication, and the ability to switch to biologic treat-
ment, enabled evaluation of the course of nonradiographic axial 
SpA and optimization of NBBMs. During the study, substantially 
more patients randomized to receive placebo switched to open- 
label CZP treatment compared to those randomized to receive 
CZP, although no switches occurred before 12 weeks. The dis-
ease activity in placebo patients switching to open- label CZP 
treatment remained high at the time of switching, as illustrated by 
the high ASDAS and BASDAI scores observed at this time point. 
This high level of disease activity suggests that in the majority of 
patients with active disease, nonradiographic axial SpA does not 
spontaneously remit and cannot be controlled with nonbiologic 
medications. This is further supported by the fact that only 11 of 
the 158 patients who were randomized to receive placebo could 
complete 52 weeks and achieve ASDAS- MI. These findings also 
highlight the limitations of nonbiologic treatments in patients 
with active disease with objective signs of inflammation in whom 
treatment with at least 2 NSAIDs was unsuccessful. This is sup-
ported by the fact that 69.6% of placebo plus NBBM patients 
had changes in their background medication over the course 
of the study, compared to 27.7% of CZP plus NBBM patients. 
There were also greater reductions in ASAS- NSAID scores for 
CZP plus NBBM patients versus placebo plus NBBM patients 
over the 52- week trial period, reflecting reduced use of nonbio-
logic background medications such as NSAIDs.
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The C- axSpAnd trial was designed to enroll patients with 
nonradiographic axial SpA who would derive the greatest benefit 
from treatment with an anti- TNF agent. To achieve this, patients 
were included in the study only if they exhibited objective signs 
of inflammation despite therapy with NSAIDs, and if they had a 
high level of clinical symptoms, including elevated BASDAI and 
spinal pain scores. Furthermore, screening radiographs were 
assessed centrally by 2 experienced readers to ensure that no 
patients with radiographic axial SpA (ankylosing spondylitis) 
were included.
Another strength of the C- axSpAnd study design is its use 
of ASDAS- MI as a primary end point. This outcome is a val-
idated, highly discriminatory measure used to assess disease 
activity, incorporating both patient self- reported and objective 
measures of disease activity (8). However, due to the weighting 
of its constituent measures, the ASDAS may be impacted by 
substantial changes in CRP level. To address this, improvement 
in signs and symptoms of disease was also measured using 
ASAS40, for which a similar effect was observed.
In conclusion, the results from this 52- week placebo- 
controlled trial indicate that nonradiographic axial SpA does not 
demonstrate spontaneous remission in the majority of patients 
with active disease. Since improvements in clinical efficacy and 
objective signs of inflammation were maintained to week 52 
in CZP- treated nonradiographic axial SpA patients, this study 
demonstrates the significant benefit of using CZP, an anti- TNF 
agent, in addition to NBBMs in patients with nonradiographic 
axial SpA exhibiting objective signs of inflammation.
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